Supplementary Online Content


Sebastian NT, Tan Y, Miller ED, et al. Association of liver-directed local therapy with overall survival in adults with metastatic intrahepatic cholangiocarcinoma. *JAMA Netw Open*. 2019;2(9):e1911154. doi:10.1001/jamanetworkopen.2019.11154

eFigure. Sequential Landmark Kaplan-Meier Curves, Stratified by Receipt of Liver-Directed Local Therapy (LDLT)


eTable. Patient and Disease Characteristics of the Propensity Matched Cohort, Stratified by Receipt of Liver-Directed Local Therapy (LDLT)

This supplementary material has been provided by the authors to give readers additional information about their work.


eFigure. Sequential Landmark Kaplan-Meier Curves, Stratified by Receipt of Liver-Directed Local Therapy (LDLT) (A) 3-Months



(B) 6 Months



(C) 12 Months



eTable. Patient and Disease Characteristics of the Propensity Matched Cohort, Stratified by Receipt of Liver-Directed Local Therapy (LDLT)

Characteristic	Chemotherapy Alone (n = 104)	Chemotherapy + LDLT (n = 104)	Р
Age			
Median (IQR)	62.0 (54 - 70)	61.5 (54.0 - 70.2)	0.76†
Sex			
Male	47 (45.2%)	46 (44.2%)	
Female	57 (54.8%)	58 (55.8%)	1.00 [‡]
Race			
White	94 (90.4%)	90 (86.5%)	
Black	8 (7.7%)	9 (8.7%)	0.55 [‡]
Other	2 (1.9%)	5 (4.8%)	
Charlson Comorbidity Score			
0	76 (73.1%)	73 (70.2%)	
1	21 (20.2%)	25 (24.0%)	0.69 [‡]
2	7 (6.7%)	5 (4.8%)	
3+	0 (0.0%)	1 (1.0%)	
Insurance Status			
No Insurance	4 (3.8%)	5 (4.8%)	
Private	55 (52.9%)	51 (49.0%)	0.83 [‡]
Government	45 (43.3%)	48 (46.2%)	
Treatment Facility			
Community Cancer Program	5 (4.8%)	5 (4.8%)	
Comprehensive Community Cancer	26 (25.0%)	32 (30.8%)	
Program			0.82 [‡]
Academic/Research	62 (59.6%)	56 (53.8%)	
Integrated Network Cancer Program	11 (10.6%)	11 (10.6%)	
Year of Diagnosis			
Median (IQR)	2011 (2009 - 2013)	2011 (2009 - 2013)	0.49†
T-Stage [§]			
1	13 (12.5%)	15 (14.4%)	

2	41 (39.4%)	36 (34.6%)	0.69 [‡]
3	40 (38.5%)	38 (36.5%)	
4	10 (9.6%)	15 (14.4%)	
Tumor Focality			
Unifocal	28 (26.9%)	35 (33.7%)	0.37 [‡]
Multifocal	76 (73.1%)	69 (66.3%)	
N-Stage [§]			
0	45 (43.3%)	46 (44.2%)	1.00 [‡]
1	59 (56.7%)	58 (55.8%)	
Bone Metastasis			
No	90 (86.5%)	95 (91.3%)	0.38 [‡]
Yes	14 (13.5%)	9 (8.7%)	
Lung Metastasis			
No	90 (86.5%)	91 (87.5%)	1.00 [‡]
Yes	14 (13.5%)	13 (12.5%)	
Distant Lymph Node Metastasis			
No	59 (56.7%)	61 (58.7%)	0.89 [‡]
Yes	45 (43.3%)	43 (41.3%)	

Abbreviations. IQR- interquartile range.

† Mann-Whitney U (Wilcoxon rank-sum) test

‡ Fisher's exact test

§ American Joint Committee on Cancer (AJCC) 7th edition